A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Clinical trial NCT04033354 · UNKNOWN
Trial details
- NCT number
- NCT04033354
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-14
- Primary completion
- 2023-12-30
- Enrollment
- 537
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.